Jeff Elton, Concerto HealthAI

Jeff Elton Jeff Elton, Ph.D., is CEO of Concerto HealthAI, a SymphonyAI portfolio company, and a 3rd generation Real World Evidence company that partners with the American Society of Clinical Oncology’s CancerLinQ initiative and healthcare providers across the U.S. Concerto develops engineered Real-World Data products designed for specific use cases ranging from regulatory submissions, post approval studies leading to label modifications and market access initiatives. Concerto’s engineered datasets are deployed in a clinical cloud environment, with AI metadata, AI Models and AI-enabled applications all aligned to generate “precision evidence” required for high priority use cases. Prior to Concerto, Dr. Elton was Managing Director, Accenture Strategy/Patient Health, where he focused on building the next generation of value and outcomes-centric business models for healthcare organizations and life science companies. He is the co-author of the widely cited book, Healthcare Disrupted (Wiley, 2016). Jeff has over 25 years of experience as a global executive and consultant in the healthcare and life sciences. He was previously Senior Vice President of Strategy and Global Chief Operating Officer at Novartis Institutes of BioMedical Research, Inc.; founding CEO of an oncology molecular diagnostics and therapeutic pathways company; and founding board member and senior advisor to several early stage companies in Artificial Intelligence, Digital Pathology, Parkinson's Disease treatment, protein therapeutics, diabetes, oncology therapeutics, and precision medicine/oncology diagnostics. Jeff is currently a board member of the Massachusetts Biotechnology Council. He is a former partner with McKinsey & Company and was adjunct faculty at Boston University, Questrom School of Business, in Health Sector Management. Jeff has a Ph.D. and M.B.A. from The University of Chicago, Booth School of Business.


9:25 AM - 9:50 AM

Innovate Practically: Finding the Intersections Between AI and RWE to Better Treat Patients

This session will cover how biopharma companies are using real world data combined with AI to enhance business value and impact. While still in the nascent stages, the practice of real-world data analytics is moving beyond primarily post-approval applications and is being institutionalized across organizations. Themes to be discussed include:

  • Overcoming cultural resistance to using real world data.
  • Adopting and effectively utilizing real-world evidence to develop the innovative medicines of the future.
  • Collaborating with strategic partners to identify specific use cases that advance your efforts and deliver beneficial therapies faster to patients.



  • Vitaly Doban

    Vitaly Doban Executive Director, Head of RWE Advanced and Applied Analytics Novartis Oncology

Download Latest Agenda